Free Trial
OTCMKTS:BVNRY

Bavarian Nordic Q4 2024 Earnings Results & Report

Bavarian Nordic logo
$11.68 -0.11 (-0.93%)
As of 09:45 AM Eastern

Bavarian Nordic beat analyst expectations on both earnings and revenue in its Q4 2024 results, released March 5, 2025. The company reported EPS of $0.47 versus the $0.40 consensus estimate, while revenue of $299.48 million topped the $264.06 million estimate by $35.42 million.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens

Bavarian Nordic EPS Results

Actual EPS
$0.47
Consensus EPS
$0.40
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Bavarian Nordic Revenue Results

Actual Revenue
$299.48 million
Expected Revenue
$264.06 million
Beat/Miss
Beat by +$35.42 million
YoY Revenue Growth
N/A

Conference Call Resources

Bavarian Nordic Q4 2024 Earnings FAQ

Bavarian Nordic (OTCMKTS:BVNRY) reported earnings of $0.47 per share for Q4 2024, beating the consensus estimate of $0.40. The report was announced on Wednesday, March 5, 2025.

Bavarian Nordic reported revenue of $299.48 million for Q4 2024, against a consensus estimate of $264.06 million.

Bavarian Nordic Earnings Headlines

Bavarian Nordic beats Q3 revenue expectations
Trump’s Invisible Dollar Reset
Porter Stansberry believes President Trump could be about to trigger the biggest change to America's money in more than 50 years, with no new bills or central bank digital currency. He points to Executive Order 14241, emergency declarations and international pacts as part of the plan, and to December 14, when Trump hosts world leaders at his Doral resort in Miami. In his view, a repricing of goods, services and assets could follow, and some assets tied to the reset have already begun to move.tc pixel
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions.

Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.

The company uses its MVA-BN technology in vaccine development and supplies products to public health authorities as well as commercial markets. Its portfolio includes vaccines developed in-house and products added through acquisitions.

View Bavarian Nordic Profile